Show simple item record

dc.contributor.authorRubin, Jaime L
dc.contributor.authorMcGarry, Lisa J
dc.contributor.authorKlugman, Keith P
dc.contributor.authorStrutton, David R
dc.contributor.authorGilmore, Kristen E
dc.contributor.authorWeinstein, Milton C.
dc.date.accessioned2011-04-23T16:52:12Z
dc.date.issued2010
dc.identifier.citationRubin, Jaime L., Lisa J. McGarry, Keith P. Klugman, David R. Strutton, Kristen E. Gilmore, and Milton C. Weinstein. 2010. Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. BMC Infectious Diseases 10: 14.en_US
dc.identifier.issn1471-2334en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:4874801
dc.description.abstractBackground: Influenza pandemic outbreaks occurred in the US in 1918, 1957, and 1968. Historical evidence suggests that the majority of influenza-related deaths during the 1918 US pandemic were attributable to bacterial pneumococcal infections. The 2009 novel influenza A (H1N1) outbreak highlights the importance of interventions that may mitigate the impact of a pandemic. Methods: A decision-analytic model was constructed to evaluate the impact of 7-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal disease incidence and mortality during a typical influenza season (13/100) and a severe influenza pandemic (30/100). Outcomes were compared for current PCV7 vaccination practices vs. no vaccination. The model was estimated using published sources and includes indirect (herd) protection of non-vaccinated persons. Results: The model predicts that PCV7 vaccination in the US is cost saving for a normal influenza season, reducing pneumococcal-related costs by $1.6 billion. In a severe influenza pandemic, vaccination would save $7.3 billion in costs and prevent 512,000 cases of IPD, 719,000 cases of pneumonia, 62,000 IPD deaths, and 47,000 pneumonia deaths; 84% of deaths are prevented due to indirect (herd) protection in the unvaccinated. Conclusions: PCV7 vaccination is highly effective and cost saving in both normal and severe pandemic influenza seasons. Current infant vaccination practices may prevent >1 million pneumococcal-related deaths in a severe influenza pandemic, primarily due to herd protection.en_US
dc.language.isoen_USen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofdoi:10.1186/1471-2334-10-14en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823614/pdf/en_US
dash.licenseLAA
dc.titlePublic health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemicen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalBMC Infectious Diseasesen_US
dash.depositing.authorWeinstein, Milton C.
dc.date.available2011-04-23T16:52:12Z
dash.affiliation.otherSPH^Center for Risk Analysisen_US
dash.affiliation.otherSPH^Health Policy and Managementen_US
dash.affiliation.otherHMS^Medicine-Brigham and Women's Hospitalen_US
dc.identifier.doi10.1186/1471-2334-10-14*
dash.contributor.affiliatedWeinstein, Milton


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record